Lorlatinib/lorlatinib tablets which company is from

Lorlatinib (Lorlatinib) is a drug used to treat ALK-positive non-small cell lung cancer (NSCLC). Larlatinibis developed and produced by the US pharmaceutical company Pfizer. As a leading global pharmaceutical company, Pfizer is committed to developing, manufacturing and marketing innovative pharmaceutical products to meet the needs of patients. The company has multiple R&D centers and production bases around the world, and has a strong scientific research team and rich experience.

Lorlatinib, Pfizer's innovative lung cancer drug, belongs to the world's third generationALK (anaplastic lymphoma kinase) inhibitor. Its research and development has gone through rigorous scientific experiments and clinical trial verification to ensure its safety and effectiveness. It inhibits the activity of ALK and ROS1 dual receptor tyrosine kinase (RTK), blocking the growth and spread of tumor cells, thereby achieving the purpose of treating non-small cell lung cancer. This mechanism makes lorlatinib more targeted and has fewer side effects during treatment. Larlatinib was approved by the U.S. Food and Drug Administration (FDA) in 2018 and has become the drug of choice for the first-line treatment of ALK-positive NSCLC. Since then, it has also been approved by other countries and regions and has become one of the important drugs for the treatment of ALK-positive NSCLC worldwide.

The launch of lorlatinib tablets not only brings good news to lung cancer patients, but also reflects Pfizer's commitment and pursuit of human health. Pfizer played an important role in its research and development process, demonstrating its outstanding strength and contribution in the field of medicine. Pfizer will continue to be committed to the research, development and production of innovative drugs to bring hope and life to more patients.